托珠单抗可阻止早期系统性硬化相关间质性肺病进展
本研究为focuSSced试验的事后分析,纳入210例系统性硬化症伴进展性皮肤病变患者,其中136例(65%)存在间质性肺病。结果显示,托珠单抗组48周内用力肺活量百分比预测值(FVC%)保持稳定(最小二乘均值变化-0.1),而安慰剂组下降(-6.3%),且该保护作用不受影像学定量间质性肺病(QILD)范围影响。
要点
- 托珠单抗治疗48周可稳定早期系统性硬化相关间质性肺病患者的FVC%。
- 安慰剂组FVC%在48周内平均下降6.3%。
- 托珠单抗对肺功能的保护作用不受QILD范围影响。
核心结论
- 在早期系统性硬化相关间质性肺病伴进展性皮肤病变患者中,托珠单抗治疗48周可稳定FVC%,且该作用独立于影像学QILD范围。
研究设计与样本
- focuSSced试验的事后分析,该试验为III期随机安慰剂对照试验,纳入210例系统性硬化症伴进展性皮肤病变患者,其中136例(65%)存在间质性肺病。
主要发现
- 托珠单抗组48周FVC%最小二乘均值变化为-0.1,安慰剂组为-6.3%。
- 轻度QILD患者中,托珠单抗组48周FVC%平均变化为-4.1±2.5%(n=11),安慰剂组为-10.0±2.6%(n=11)。
- 中度QILD患者中,托珠单抗组48周FVC%平均变化为0.7±1.9%(n=19),安慰剂组为-5.7±1.6%(n=26)。
- 重度QILD患者中,托珠单抗组48周FVC%平均变化为2.1±1.6%(n=26),安慰剂组为-6.7±2.0%(n=16)。
- 类似的治疗相关肺功能保护作用在不同纤维化严重程度中均可见。
关键数值与推荐
- QILD分级:轻度为>5-10%,中度为>10-20%,重度为>20%。
- 中重度受累定义为肺受累>10%,占间质性肺病患者的77%。
临床怎么用
- 对于早期系统性硬化相关间质性肺病伴进展性皮肤病变的患者,可考虑使用托珠单抗以稳定肺功能。
局限性
- 本研究为事后分析,原始试验主要终点并非肺功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of radiographically evident quantitative lung involvement. We undertook this study to assess the impact of TCZ on lung function preservation in a post hoc analysis, stratifying treatment arms according to the degree of lung involvement. METHODS: The focuSSced trial was a phase III randomized placebo-controlled trial of TCZ in patients with SSc and progressive skin disease. Participants underwent baseline and serial spirometry along with high-resolution chest computed tomography at baseline and at week 48. Quantitative interstitial lung disease (QILD) and fibrosis scores were assessed by computer software. We classified QILD into the following categories of lung involvement: mild (>5-10%), moderate (>10-20%), and severe (>20%). RESULTS: Of 210 participants recruited for the trial, 136 patients (65%) had ILD. The majority of these patients (77%) had moderate-to-severe involvement (defined as >10% lung involvement). The TCZ arm demonstrated preservation of forced vital capacity percent predicted (FVC%) over 48 weeks (least squares mean change in FVC% = -0.1) compared to placebo (-6.3%). For mild, moderate, and severe QILD, the mean ± SD change in FVC% in the TCZ arm at 48 weeks were -4.1 ± 2.5% (n = 11), 0.7 ± 1.9% (n =19), and 2.1 ± 1.6% (n = 26), respectively, and in the placebo group were -10.0 ± 2.6% (n = 11), -5.7 ± 1.6% (n = 26), and -6.7 ± 2.0% (n = 16), respectively. Similar treatment-related preservation findings were seen independent of fibrosis severity. CONCLUSION: TCZ in early SSc-associated ILD with progressive skin disease stabilized FVC% over 48 weeks, independent of the extent of radiographically evident QILD.
引用
- Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021. PMID: 33538094. doi:10.1002/art.41668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。